Ypsomed : Presentation of Half-Year Results 2025/26

About this update from Ypsomed Holding Ag

Ypsomed Half Year Results 2025/26 Transforming selfcare, Transforming Ypsomed Webcast, 12 November 2025 Important information The information contained in this document has not been verified by an independent source. It should be taken with caution, and no assurance or guarantee is given (either explicit or implied) regarding the fairness, accuracy, completeness or correctness of the information or opinions contained herein. Neither Ypsomed Holding AG nor advisors or affiliates of Ypsomed Holding AG shall be liable in any way for losses occurred in conjunction with the use of this document, its contents or any other connection with this document. This document is neither an offer (or part of an offer) for the sale, nor a solicitation for the purchase of shares, and neither the document nor parts thereof form the basis of any contract or otherwise obligation. This document contains future-oriented statements which include uncertainties and risks. Such statements are indicated by such words as "could", "planned", "expected", "believed" and similar expressions or their context. These statements are made based on current knowledge and current assumptions. Due to a variety of different factors, the actual future results, developments or events may deviate considerably from those mentioned here. There is no obligation whatsoever to update future-oriented statements. Our purpose is to make selfcare simpler and easier Ypsomed benefits from structural growth drivers Thanks to its clear strategic focus and solid structure, Ypsomed is uniquely positioned to benefit from significant growth in the end market Pure-play injection specialist Innovation leadership Operational excellence Strong financials Ypsomed is a pure-play injection specialist Pure-play injection specialist Innovation leadership Operational excellence Strong financials Ypsomed has completed its transformational journey to become a pure-play self-injection specialist Ypsomed is now a pure play self-injection specialist 2025 2025 2024 2023 2022 Completion of the sale of Ypsotec Completion of the sale of the diabetes care business Completion of the sale of the pen needle and BGM business Completion of the sale of the DiaExpert retail business in Germany Transformation from matrix structure to an organization with product areas Ypsomed's new starting point - Delivery Systems generated revenue of CHF 267 million in the first half of the financial year 2025/26 Revenue contribution HY 2025/26 (in mCHF) Revenue contribution mid-term 21 75 267 Delivery Systems Diabetes Care Other Ypsomed is a leader in the innovation of delivery systems Pure-play injection specialist Innovation leadership Operational excellence Strong financials Ypsomed has the widest range of self-injection solutions on the market

View stock analysis, news, and events for Ypsomed Holding Ag